ILSI-Biomed Israel

Vaxil’s TB vaccine successfully passes first stage in animal studies

Nes-Ziona, 8th March, 2011. Vaxil Biotherapeutics Ltd., a clinical stage developer of innovative therapeutic vaccines announced today that MTbuVax, its vaccine against the lethal bacteria Mycobacterium Tuberculosis (MTb) has proven to manifest effective induction of immune response in mice. The studies demonstrated that mice vaccinated with MTbuVax produced potent CD4+ and CD8+ T-cell immunity that specifically proliferated in response to the MTbuVax vaccine. In addition, T-cells from vac...

Meet The Speakers: Prof. Regina E. Herzlinger

Prof. Regina Herzlinger will give a keynote lecture in the up-and-coming ILSI-BioMed week at the first day, Monday, May 23 2011. Regina E. Herzlinger is the Nancy R. McPherson Professor of Business Administration at the Harvard Business School. She was the first woman to be tenured and chaired at Harvard Business School and the first to serve on a number of corporate boards. She is widely recognized for her innovative research in health care, including her early predictions of the unraveling of ...

A film which explains about a new therapeutic vaccine for cancer – amazing!

Here is the film which explains about ImMucin, a new therapeutic vaccine for cancer which is currently in clinical trials in Myeloma patients. You are also invited to visit Vaxil BioTherapeutics site. Tweet

PROLOR BIOTECH SIGNS EXCLUSIVE LICENSE AGREEMENT WITH YEDA FOR ANTI-OBESITY APPLICATIONS

PROLOR Biotech, Inc., (NYSE Amex: PBTH), announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a variety of peptides and small molecules, including the diab...

Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea

The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds. Foamix Ltd., a clinical-stage specialty pharmaceutical company focused on the development of proprietary dermatological and gynecologic topical products, today announced enrollment of the first patient in a Phase II trial of its Topical Minocycline Foam. The double-blind, placebo controlled dose range finding study aims to ...

Molecular imaging to diagnose, monitor and treat disease

Molecular probes from Israel's Aposense show areas of disease on a cellular level and can even provide a picture that reveals the efficacy of chemotherapy. Israeli biotech company Aposense offers a futuristic way of diagnosing, monitoring and treating disease through molecules designed to detect cell death (apoptosis). While apoptosis is a universal process in cell biology, it plays a role in most medical disorders. Targeting cells undergoing apoptosis, for imaging or delivering therapy, can ...

Research at Rambam: One Session of Waterpipe Smoking May Significantly Affect Health

Rambam researchers have shown that even one waterpipe session significantly affected users’ lung function, and increased blood pressure and pulse. It boosted amounts of the toxin carboxyhemoglobin to levels that may require medical attention, oxygen administration or hyperbaric treatment. To achieve this toxic level, one must smoke between 10-100 cigarettes. Additionally, levels of exhaled NO, a molecule that helps protect the heart, lung and blood vessels greatly decreased. Research subjec...

Brainsway reports improvements in Australian autism trial

Brainsway Ltd. (TASE:BRIN) reports that interim results of an Australian study showed small but significant improvement in patients with autism or Asperger's syndrome treated with its Deep TMS (transcranial magnetic stimulation) device. The study showed improvement in the Theory of Mind (a designated coil for treating autism) and in social communications. The study conducted at the Monash Alfred Psychiatry Research Centre in Melbourne included 16 healthy adults and 20 patients with autis...

Mazor wins FDA approval for Emerald spine implants

Mazor Robotics Ltd. (TASE:MZOR) has obtained US Food and Drug Administration (FDA) marketing approval for its Emerald spinal implants. The company plans to begin marketing in the second half of 2011. Mazor's share price jumped 11 percent in heavy trading on the news, but fell back to a gain of 7.4 percent in afternoon trading to NIS 10.81, giving a market cap of NIS 204 million. The Emerald spinal implant is inserted by the company's robotic SpineAssist system for minimally invasive sp...

Out, Damn’d Spot! Hand Washing Combats Deadly Infections

Hospitals are hothouses for bacteria and viruses – sometimes deadly – that are often passed from patient to patient by the medical staff. An innovative Israeli device, already operating at Rambam, monitors the medical team to ensure proper hand-washing. Hospital-acquired diseases and infections have reached plague-like proportions in medical centers around the world. In the USA alone, close to 100,000 deaths and expenditure of some $30 billion yearly result from preventable illnesses contract...